ID   Namalwa KJM-1
AC   CVCL_4Y60
SY   Namalva KJM-1
DR   cancercelllines; CVCL_4Y60
DR   TOKU-E; 3616
DR   Wikidata; Q54907448
RX   DOI=10.1007/978-94-011-2044-9_9;
RX   PubMed=1366592;
RX   PubMed=1369278;
RX   PubMed=22358567;
CC   Group: Serum/protein free medium cell line.
CC   Population: African; Kenyan.
CC   Virology: Contains 2 integrated copies of EBV genome on chromosome 1.
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line).
CC   Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
DI   NCIt; C27694; EBV-related Burkitt lymphoma
DI   ORDO; Orphanet_543; Burkitt lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0067 ! Namalwa
SX   Female
AG   Children
CA   Cancer cell line
DT   Created: 14-12-15; Last updated: 05-10-23; Version: 15
//
RX   DOI=10.1007/978-94-011-2044-9_9;
RA   Hosoi S., Satoh M., Miyaji H., Nishi T., Mizukami T., Hasegawa M.,
RA   Itoh S., Tamaoki T.;
RT   "Stable production of pro-urokinase and its derivative by Namalwa KJM-1
RT   cells adapted to a serum-free medium.";
RL   (In) Animal cell technology. Basic and applied aspects, Vol. 5; Kaminogawa S., Ametani A., Hachimura S. (eds.); pp.63-70; Springer; Dordrecht (1993).
//
RX   PubMed=1366592; DOI=10.1007/BF00143675;
RA   Miyaji H., Mizukami T., Hosoi S., Sato S., Fujiyoshi N., Itoh S.;
RT   "Expression of human beta-interferon in Namalwa KJM-1 which was
RT   adapted to serum-free medium.";
RL   Cytotechnology 3:133-140(1990).
//
RX   PubMed=1369278; DOI=10.1007/BF00148809;
RA   Miyaji H., Harada N., Mizukami T., Sato S., Fujiyoshi N., Itoh S.;
RT   "Expression of human lymphotoxin in Namalwa KJM-1 cells adapted to
RT   serum-free medium.";
RL   Cytotechnology 4:39-43(1990).
//
RX   PubMed=22358567; DOI=10.1007/BF00146816;
RA   Hosoi S., Mioh H., Anzai C., Sato S., Fujiyoshi N.;
RT   "Establishment of Namalva cell lines which grow continuously in
RT   glutamine-free medium.";
RL   Cytotechnology 1:151-158(1988).
//